Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy

Authors

  • Rajendra Kumar Parakh Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India
  • Neelakanth S. Patil Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20180005

Keywords:

Aluminium hydroxide, Anaesthetic antacids, Hyperacidity, Magnesium hydroxide, Oxethazaine, Peptic ulcer

Abstract

Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids. Antacids vary widely in their in vitro acid neutralizing capacity (ANC), which measures the potency. Among marketed brands in India, Digecaine has shown the highest potency with maximum mean ANC value (28.84 mEq). The expert panel has recommended the inclusion of oxethazaine-antacid/alginate-antacid as complementary to the proton pump inhibitors in the management algorithm of gastroesophageal reflux disease. The present review summarizes the pharmacokinetic and pharmacodynamic of different components of anaesthetic antacids and its clinical use across different gastrointestinal indications, for generalists and specialists, based on existing evidences.

References

1. Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57:855-70.
2. Sabesin SM. Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Aliment Pharmacol Ther. 1993;7(Suppl 2):35-40.
3. Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et al. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295-302.
4. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, et al. New algorithm for the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:249-56.
5. Ogilvie AL, Atkinson M. Does dimethicone increase the efficacy of antacids in the treatment of reflux esophagitis? J R Soc Med. 1986;79:584-87.
6. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14:669-90.
7. Hsu MC, Lin SF, Kuan CP, Chu WL, Chan KH, Chang-Chien GP. Oxethazaine as the source of mephentermine and phentermine in athlete's urine. Forensic Sci Int. 2009;185:e1-5.
8. Presle N, Lapicque F, Gillet P, Herrmann MA, Bannwarth B, Netter P. Effect of dimethicone (polysilane gel) on the stereoselective pharmacokinetics of ketoprofen. Eur J Clin Pharmacol. 1998;54:351-4.
9. Panda V, Shinde P, Deora J, Gupta P. A comparative study of the antacid effect of some commonly consumed foods for hyperacidity in an artificial stomach model. Complement Ther Med. 2017;34:111-5.
10. Wallace JL. Recent advances in gastric ulcer therapeutics. Curr Opin Pharmacol. 2005;5:573-7.
11. Novaes CC, Richards DJ, Davis GR. A comparison of the acid neutralizing effects of a combination of antacid plus oxethazaine (Oxaine M) compared to antacid alone (Aludrox) in duodenal ulcer patients. Curr Ther Res Clin Exp. 1975;18:124-31.
12. Rider JA, Moeller HC, Gardey RH. Oxethazaine hydrochloride for treatment of gastritis, peptic ulcer and esophagitis. Clin Med (Northfield). 1963;70:1271-8.
13. Pontes JF, Richards DJ, Sartoretto JN. Double-blind comparison of an oxethazaine-antacid combination (Oxaine M) against the antacid alone (Aludrox) in the treatment of duodenal ulcer pain. Curr Ther Res Clin Exp. 1975;18:315-23.
14. Chiba N, Fennerty, MB. Gastroesophageal reflux disease. Evidence-based gastroenterology & hepatology. Third edition. Editor: John W.D. McDonald, Andrew K. Burroughs, Brian G. Feagan, M. Brian Fennerty. 2010:19.
15. Tran T, Lowry AM, E - Serag HB. Meta-analysis: The efficacy of over - the - counter gastro - esophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25:143-53.
16. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949-58.
17. Kua CH, Ng ST, Lhode R, Kowalski S, Gwee KA. Irritable bowel syndrome and other gastrointestinal disorders: Evaluating self-medication in an Asian community setting. Int J Clin Pharm. 2012;34:561-8.
18. Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Faresjo T, Timpka T. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm. 2008;14:870-7.
19. Ingle M, Abraham P. Management of functional dyspepsia. J Assoc Phys Ind. 2012;60:25-7.
20. Bailey J, Carter NJ, Neher JO. FPIN's Clinical Inquiries: Effective management of flatulence Am Fam Phys. 2009;79:1098.
21. Hanauer SB, DuPont HL, Cooper KM, Laudadio C. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007;23:1033-43.
22. Bhoir S, Bhagwat AM. Comparison of seven Oxethazaine containing antacids available in the Indian market. J Assoc Physicians India. 2013;61:400-3.
23. Siffert G. Addition of oxethazaine to a standard antacid in treatment of duodenal ulcer. Curr Med Res Opin. 1972;1:139-43.
24. Zanni A, Gherardi S, Crowther PS, De Tomasi F, Scott CN, Bertoli R. A double-blind controlled study to compare the efficacy of an antacid plus oxethazaine with that of an antacid alone in the treatment of pain due to gastric or duodenal ulceration. Curr Med Res Opin. 1986;10:128-34.
25. Carne S. Double-blind trial of mucaine in heartburn of pregnancy. J Coll Gen Pract. 1964;8:135-39.
26. Kovacs GT, Campbell J, Francis D, Hill D, Adena MA. Is mucaine an appropriate medication for the relief of heartburn during pregnancy? Asia Oceania J Obstet Gynaecol. 1990;16:357-62.
27. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther. 2002;16:1641-8.
28. Jacyna MR, Boyd EJ, Wormsley KG. Comparative study of four antacids. Postgrad Med J. 1984;60:592-6.
29. Hollander E. Oxethazaine for control of symptoms in refractory cases of duodenal ulcer and hiatus hernia. Am J Gastroenterol. 1960;34:613-8.
30. Richter JE. The management of heartburn in pregnancy (Review article). Aliment Pharmacol Ther. 2005;22:749-57.
31. Tytgat GN, Heading RC, Muller-Lissner S, Kamm MA, Schölmerich J, Berstad A, et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther. 2003;18:291-101.
32. Lindow SW, Regnell P, Sykes J, Little S. An open-label multicenter study to assess the safety and efficacy of a novel reflux supplement (Gaviscon advance) in the treatment of heartburn of pregnancy. Int J Clin Pract. 2003;57:175-9.
33. Gioiella G, Crispo S, Mainiero P, Baktyari S, Ambrosio SD, Canero A, et al. Clinical study on the pharmacological treatment of hemorrhoids with 0.25% oxetacaine chlorhydrate. Clin Ter. 2004;155:443-5.
34. Miner PB, Allgood LD, Grender LM. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther. 2006;25:103-9.
35. de Argila CM and Belinchon MR. Combined Therapy (PPI Plus Antacid) for a Better Control of Symptoms in Patients With GERD: A Survey on Primary Care in Spain.(Poster) Gastroenterol. 2013;144(Suppl 1):S-858.
36. Tytgat GN, Simoneau G. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension. Aliment Pharmacol Ther. 2006;23:759-65.
37. Tack J. Review article: role of pepsin and bile acid in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2005;22(Suppl 1):48-54.
38. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-28.
39. Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5:105-12.
40. Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-67.

Downloads

Published

2018-01-24

How to Cite

Parakh, R. K., & Patil, N. S. (2018). Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy. International Journal of Research in Medical Sciences, 6(2), 383–393. https://doi.org/10.18203/2320-6012.ijrms20180005

Issue

Section

Review Articles